💊 Lupin Receives Tentative U.S. FDA Approval for Enzalutamide Tablets

📢 Key Update** **Lupin Ltd.** has received **tentative approval from the U.S. FDA** for its **Enzalutamide Tablets** in **40 mg, 80 mg, 120 mg, and 160 mg** strengths through its Abbreviated New Drug Application (ANDA). ### 🔍 What Has Been Approved? * ✅ **40 mg & 80 mg tablets** are **bioequivalent** to **Xtandi®** (reference listed drug by Astellas). * ✅ Lupin has also secured **tentative approval** for **120 mg & 160 mg** strengths, offering **additional dosing flexibility** for healthcare providers and patients. ### 🏥 About Enzalutamide Enzalutamide is used in the treatment of **prostate cancer**, making it an important product in the oncology segment. ### 📈 Why This Matters for Investors * 🇺🇸 Strengthens Lupin's U.S. generic pipeline. * 💊 Expands the company's oncology portfolio. * ⚖️ Commercial launch will depend on the expiry of existing patents/exclusivity despite the tentative approval. * 🌍 Reinforces Lupin's long-term strategy of growing its complex generics business in regulated markets. **What do you think—can oncology generics become a stronger growth driver for Lupin over the next few years? Share your thoughts below.** 👍 Like | 🔄 Share | ➕ Follow **AFS Trading Edge** for timely market and corporate updates. *Disclaimer: This post is for educational and informational purposes only and should not be construed as investment advice. Please conduct your own research before making any investment decisions.